Artificial intelligence guided screening for cardiomyopathies in an obstetric population
The SPEC-AI Nigeria trial evaluated AI-guided ECG-based screening vs. clinical ECGs alone for identifying cardiomyopathy among pregnant/postpartum women in Nigeria, utilizing AI algorithms for ECG analysis. The trial, funded by Mayo Clinic and NIH, involved six hospitals, with participants aged 18-49, randomized to AI-guided screening or standard ECG, followed up to 12 months postpartum. The primary outcome was identification of LVEF < 50% by echocardiography, with secondary outcomes including AI model performance and effectiveness in identifying various LVEF levels.
Related Clinical Trials
Reference News
AI-enhanced digital stethoscope 12x more likely to detect peripartum cardiomyopathy, a pregnancy-linked heart failure, than traditional methods, per clinical trial. 4% of women using AI stethoscope diagnosed, vs. 2% with traditional care. Study conducted in Nigeria, plans for U.S. trials.
The SPEC-AI Nigeria trial evaluated AI-guided ECG-based screening vs. clinical ECGs alone for identifying cardiomyopathy among pregnant/postpartum women in Nigeria, utilizing AI algorithms for ECG analysis. The trial, funded by Mayo Clinic and NIH, involved six hospitals, with participants aged 18-49, randomized to AI-guided screening or standard ECG, followed up to 12 months postpartum. The primary outcome was identification of LVEF < 50% by echocardiography, with secondary outcomes including AI model performance and effectiveness in identifying various LVEF levels.